Safety of Canagliflozin in Patients with Type 2 Diabetes

By  

Current Drug Safety, Vol. 9, Iss. 2, 2014-07 ,pp. : 127-132

Bentham Science Publishers

Access to resources Recommend Favorite

A randomized, double‐blind, placebo‐controlled study on long‐term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the Long‐Term ASP1941 Safety Evaluation in Patients with Type 2 Diabetes with Renal Impairment (LANTERN) study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 2, 2015-02 ,pp. : 152-160

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study

By Seino Yutaka   Fujita Tetsuya   Hiroi Shinzo   Hirayama Masashi   Kaku Kohei  

Current Medical Research and Opinion, Vol. 27, Iss. 9, 2011-09 ,pp. : 1781-1792

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double‐blind, placebo‐controlled, parallel‐group comparative study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 2, 2018-02 ,pp. : 453-457

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy of prolonged release melatonin in insomnia patients aged 55–80 years: quality of sleep and next-day alertness outcomes

By Wade Alan G   Ford Ian   Crawford Gordon   McMahon Alex D   Nir Tali   Laudon Moshe   Zisapel Nava  

Current Medical Research and Opinion, Vol. 23, Iss. 10, 2007-10 ,pp. : 2597-2605

Informa Healthcare

Access to resources Recommend Favorite